Comparison between photodynamic therapy with ranibizumab and fixed dosing aflibercept for polypoidal choroidal vasculopathy

Comparison between photodynamic therapy with ranibizumab and fixed dosing aflibercept for polypoidal choroidal vasculopathy - Comparison between photodynamic therapy with ranibizumab and fixed dosing aflibercept for polypoidal choroidal vasculopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029148

Enrollment

Registered

2017-09-15

Start date

2017-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polypoidal choroidal vasculopathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who were diagnosed with polypoidal choroidal vasculopathy(PCV) and were initially treated between November 2009 and November 2013 2)Minimum follow-up period of 2 years.

Exclusion criteria

Exclusion criteria: 1)Concurrent ocular diseases affecting visual acuity 2)Previous treatment for PCV 3)History of intraocular surgery other than phacoemulsification

Design outcomes

Primary

Measure	Time frame
The change of best-corrected visual acuity 3, 12 and 24 months after treatment	—

Countries

Japan

Contacts

Public ContactAi Yoneda

The Japanese Red Cross Nagasaki Genbaku Hospital Department of Ophthalmology

aiyoneda@nagasaki-med.jrc.or.jp095-847-1511

Outcome results